Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
@article{Hallek2010AdditionOR, title={Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial}, author={M. Hallek and K. Fischer and G. Fingerle-Rowson and A. Fink and the German Chronic Lymphocytic Leukaemia Study Group}, journal={The Lancet}, year={2010}, volume={376}, pages={1164-1174} }
BACKGROUND
On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.
METHODS
Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to
see how well they work compared to fludarabine and cyclophosphamide in treating patients with… Expand
Conditions | Leukemia |
---|---|
Intervention | Drug |
Topics from this paper
Paper Mentions
Interventional Clinical Trial
Study Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of
Patients with Early Stage CLL With High Risk of Early Disease Progression.
The study… Expand
Conditions | Chronic Lymphocytic Leukemia- Binet Staging System |
---|---|
Intervention | Drug |
Interventional Clinical Trial
In previously-untreated subjects with CLL, fludarabine and rituximab with or without
cyclophosphamide (FR or FCR) produces complete responses (CR) of 40-80%. The major
complication… Expand
Conditions | Chronic Lymphocytic Leukemia (CLL) |
---|---|
Intervention | Drug |
Interventional Clinical Trial
The investigators would like to propose a phase-2 prospective multicenter trial evaluating
the efficacy of rituximab combination with our current chemotherapy strategy for adult Acute… Expand
Conditions | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
---|---|
Intervention | Drug |
1,583 Citations
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
- Medicine
- The Lancet. Oncology
- 2016
- 331
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
- Medicine
- Leukemia research
- 2014
- 9
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
- Medicine
- The Lancet. Haematology
- 2018
- 10
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2011
- 347
- PDF
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2012
- 371
- PDF
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
- Medicine
- Blood
- 2013
- 48
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
- Medicine
- Leukemia & lymphoma
- 2013
- 22
Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial
- Medicine
- Expert review of anticancer therapy
- 2011
- 12
References
SHOWING 1-10 OF 41 REFERENCES
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
- Medicine
- Blood
- 2006
- 607
- PDF
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
- Medicine
- Blood
- 2002
- 203
- PDF
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2005
- 523
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2007
- 272
- PDF
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
- Medicine
- Blood
- 2008
- 659
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2005
- 939
- PDF
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2001
- 608